{"id":"nct:NCT00129389","kind":"trial","title":"FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients","authors":["Spanish Breast Cancer Research Group"],"author_count":1,"year":2005,"published":"2005-08-11","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT00129389","source_url":"https://clinicaltrials.gov/study/NCT00129389","archive_url":"https://space-kitty.com/papers/nct:NCT00129389","updated":"2023-03-07","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This is a prospective, open-label, randomized, phase III trial. Patients will be stratified after breast surgery, as per investigational site; menopausal status; node negative diagnosis, as per sentinel-node technique versus lymphadenectomy; hormone receptor status (positive versus negative).","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Breast Cancer"],"details":{"acronym":null,"status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":1925,"sponsor":"Spanish Breast Cancer Research Group","conditions":["Breast Cancer"],"interventions":["DRUG: Fluorouracil","DRUG: Doxorubicin","DRUG: Cyclophosphamide","DRUG: Paclitaxel"],"start_date":"2003-09-19","start_date_type":"ACTUAL","primary_completion_date":"2013-10-01","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"gene-cell-therapy","name":"Gene & Cell Therapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}